Soluble epoxide hydrolase inhibitors and cardiovascular diseases

Zhen He Wang, Benjamin B. Davis, De Qian Jiang, Ting Ting Zhao, Dan Yan Xu

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemiareperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular diseases, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the treatment of cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalCurrent Vascular Pharmacology
Volume11
Issue number1
StatePublished - 2013

Keywords

  • Cardiovascular diseases
  • Epoxyeicosatrienoic acids
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Soluble epoxide hydrolase inhibitors and cardiovascular diseases'. Together they form a unique fingerprint.

  • Cite this

    Wang, Z. H., Davis, B. B., Jiang, D. Q., Zhao, T. T., & Xu, D. Y. (2013). Soluble epoxide hydrolase inhibitors and cardiovascular diseases. Current Vascular Pharmacology, 11(1), 105-111.